SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] S-1: (Original Filing)

[CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to Be Registered Amount to Be Registered] [UNDERWRITING AGREEMENT between SKYSTAR BIO-PHARMACEUTICAL COMPANY and RODMAN & RENSHAW, LLC as Representative SKYSTAR BIO-PHARMACEUTICAL COMPANY UNDERWRITING AGREEMENT New York, New York ___________ __, 2010 Rodman & Renshaw, LLC th 1251 Avenue of the Americas, 20 New York, New York 10020 Ladies and Gentlemen: Company Representative Underwriters Underwriter 1. Purchase and Sale of Securities. 1.1 Firm Securities 1.1.1. Nature and] [Form of Representative’s Option Agreement THE REGISTERED HOLDER OF THIS PURCHASE OPTION BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE OPTION EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE OPTION AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE OPTION FOR A PERIOD OF ONE HUNDRED] [RICHARDSON & PATEL LLP 10900 Wilshire Boulevard Suite 500 Los Angeles, California 90024 Telephone (310) 208-1183 Facsimile (310) 208-1154 ___________________, 2010 SKYSTAR BIO-PHARMACEUTICAL COMPANY Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China Re: SKYSTAR BIO-PHARMACEUTICAL COMPANY Ladies and Gentlemen: In connection with this opinion, we have examined originals or copies of the registration statement,] [Consent of Independent Registered Public Accounting Firm To the Board of Directors Skystar Bio-Pharmaceutical Company We consent to the use of our report dated March 31, 2010, with respect to the consolidated financial statements of Skystar Bio-Pharmaceutical Company and Subsidiaries (the “Company”) as of December 31, 2009 and 2008 and for the related statements of income and other comprehensive income,]

By | 2016-03-01T06:05:47+00:00 June 1st, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] S-1: CALCULATION OF REGISTRATION FEE Title of Each Class

[CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to Be Registered Amount to Be Registered] [UNDERWRITING AGREEMENT between SKYSTAR BIO-PHARMACEUTICAL COMPANY and RODMAN & RENSHAW, LLC as Representative SKYSTAR BIO-PHARMACEUTICAL COMPANY UNDERWRITING AGREEMENT New York, New York ___________ __, 2010 Rodman & Renshaw, LLC th 1251 Avenue of the Americas, 20 New York, New York 10020 Ladies and Gentlemen: Company Representative Underwriters Underwriter 1. Purchase and Sale of Securities. 1.1 Firm Securities 1.1.1. Nature and] [Form of Representative’s Option Agreement THE REGISTERED HOLDER OF THIS PURCHASE OPTION BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE OPTION EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE OPTION AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE OPTION FOR A PERIOD OF ONE HUNDRED] [RICHARDSON & PATEL LLP 10900 Wilshire Boulevard Suite 500 Los Angeles, California 90024 Telephone (310) 208-1183 Facsimile (310) 208-1154 ___________________, 2010 SKYSTAR BIO-PHARMACEUTICAL COMPANY Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China Re: SKYSTAR BIO-PHARMACEUTICAL COMPANY Ladies and Gentlemen: In connection with this opinion, we have examined originals or copies of the registration statement,] [Consent of Independent Registered Public Accounting Firm To the Board of Directors Skystar Bio-Pharmaceutical Company We consent to the use of our report dated March 31, 2010, with respect to the consolidated financial statements of Skystar Bio-Pharmaceutical Company and Subsidiaries (the “Company”) as of December 31, 2009 and 2008 and for the related statements of income and other comprehensive income,]

By | 2016-03-01T06:06:43+00:00 June 1st, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] S-1: (Original Filing)

[CALCULATION OF REGISTRATION FEE TitleofEachClassofSecuritiestoBeRegistered AmounttoBe Registered ProposedMaximumgregateOffering (1) Price Amountof RegistrationFee (2) Shares ofmmon Stock, $.001 par value $ 28,750,000 $ 2,049.88 (3) (4) Underwritersmmon Stock Purchase Option 1 option $ 100 $ - Shares ofmmon Stock underlying Underwritersmmon Stock Purchase Option $ 781,250 $] [UNDERWRITINGREEMENT betweenYSTAR BIO-PHARMACEUTICALMPANY and RODMAN & RENSHAW, RepresentativeYSTAR BIO-PHARMACEUTICALMPANY UNDERWRITINGREEMENT New York, New York ___________ __, 2010 Rodman & Renshaw, th 1251 Avenue of the Americas, 20 New York, New York 10020 Ladies and Gentlemen:mpany Representative Underwriters Underwriter 1. Purchase andle of Securities.] [Form of Representatives Optionreement THE REGISTERED HOLDER OF THIS PURCHASE OPTION BY ITS ACCEPTANCE HEREOF,REES THAT IT WILL NOT SELL, TRANSFER ORSIGN THIS PURCHASE OPTION EXCEPT HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE OPTIONREES THAT IT WILL NOT SELL, TRANSFER,SIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE OPTION FOR A PERIOD OF ONE HUNDRED EIGHTYYS] [RICHARDSON & PATEL 10900 Wilshire Boulevard Suite 500 Los Angeles,lifornia 90024 Telephone (310) 208-1183 Facsimile (310) 208-1154 ___________________, 2010YSTAR BIO-PHARMACEUTICALMPANY Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China Re:YSTAR BIO-PHARMACEUTICALMPANY Ladies and Gentlemen: Innnection with this opinion, we have examined originals orpies of the registration statement, the proceedings of] [Consent of Independent Registered Public Accounting Firm To the Board of Directorsystar Bio-Pharmaceuticalmpany Wensent to the use of our reportted March 31, 2010, with respect to thensolidated financial statements ofystar Bio-Pharmaceuticalmpany and Subsidiaries (thempany) of December 31, 2009 and 2008 and for the related statements ofome and othermprehensiveome, shareholders equity andsh flows for each of]

By | 2016-02-05T04:14:39+00:00 June 1st, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] S-1: CALCULATION OF REGISTRATION FEE TitleofEachClassofSecuritiestoBeRegistered AmounttoBe Registered ProposedMaximumgregateOffering

[CALCULATION OF REGISTRATION FEE TitleofEachClassofSecuritiestoBeRegistered AmounttoBe Registered ProposedMaximumgregateOffering (1) Price Amountof RegistrationFee (2) Shares ofmmon Stock, $.001 par value $ 28,750,000 $ 2,049.88 (3) (4) Underwritersmmon Stock Purchase Option 1 option $ 100 $ - Shares ofmmon Stock underlying Underwritersmmon Stock Purchase Option $ 781,250 $] [UNDERWRITINGREEMENT betweenYSTAR BIO-PHARMACEUTICALMPANY and RODMAN & RENSHAW, RepresentativeYSTAR BIO-PHARMACEUTICALMPANY UNDERWRITINGREEMENT New York, New York ___________ __, 2010 Rodman & Renshaw, th 1251 Avenue of the Americas, 20 New York, New York 10020 Ladies and Gentlemen:mpany Representative Underwriters Underwriter 1. Purchase andle of Securities.] [Form of Representatives Optionreement THE REGISTERED HOLDER OF THIS PURCHASE OPTION BY ITS ACCEPTANCE HEREOF,REES THAT IT WILL NOT SELL, TRANSFER ORSIGN THIS PURCHASE OPTION EXCEPT HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE OPTIONREES THAT IT WILL NOT SELL, TRANSFER,SIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE OPTION FOR A PERIOD OF ONE HUNDRED EIGHTYYS] [RICHARDSON & PATEL 10900 Wilshire Boulevard Suite 500 Los Angeles,lifornia 90024 Telephone (310) 208-1183 Facsimile (310) 208-1154 ___________________, 2010YSTAR BIO-PHARMACEUTICALMPANY Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China Re:YSTAR BIO-PHARMACEUTICALMPANY Ladies and Gentlemen: Innnection with this opinion, we have examined originals orpies of the registration statement, the proceedings of] [Consent of Independent Registered Public Accounting Firm To the Board of Directorsystar Bio-Pharmaceuticalmpany Wensent to the use of our reportted March 31, 2010, with respect to thensolidated financial statements ofystar Bio-Pharmaceuticalmpany and Subsidiaries (thempany) of December 31, 2009 and 2008 and for the related statements ofome and othermprehensiveome, shareholders equity andsh flows for each of]

By | 2016-02-05T04:15:10+00:00 June 1st, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[NEWS RELEASE Skystar Bio-Pharmaceutical Reports 27% Growth in Revenue From Continuing Operations in First Quarter Fiscal Year 2010 Gross Margin of 53%; $0.15 Diluted Earnings Per Share; Fiscal 2010 Top Line Guidance Increased to $45.5 Million to $47.5 Million XI’AN, CHINA – May 18, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), First Quarter 2009 Highligh ts]

By | 2016-03-01T06:07:27+00:00 May 18th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: NEWS RELEASE Skystar Bio-Pharmaceutical Reports 27% Growth in

[NEWS RELEASE Skystar Bio-Pharmaceutical Reports 27% Growth in Revenue From Continuing Operations in First Quarter Fiscal Year 2010 Gross Margin of 53%; $0.15 Diluted Earnings Per Share; Fiscal 2010 Top Line Guidance Increased to $45.5 Million to $47.5 Million XI’AN, CHINA – May 18, 2010 -- - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), First Quarter 2009 Highligh ts]

By | 2016-03-01T06:08:15+00:00 May 18th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)

[NEWS RELEASEystar Bio-Pharmaceutical Reports 27% Growth in Revenue Fromntinuing Operations in First Quarter Fiscal Year 2010 Gross Margin of 53%; $0.15 Diluted Earnings Per Share; Fiscal 2010 Top Line Guidancereased to $45.5 Million to $47.5 Million XIAN, CHINA May 18, 2010 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"),]

By | 2016-02-05T04:16:31+00:00 May 18th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: NEWS RELEASEystar Bio-Pharmaceutical Reports 27% Growth in Revenue

[NEWS RELEASEystar Bio-Pharmaceutical Reports 27% Growth in Revenue Fromntinuing Operations in First Quarter Fiscal Year 2010 Gross Margin of 53%; $0.15 Diluted Earnings Per Share; Fiscal 2010 Top Line Guidancereased to $45.5 Million to $47.5 Million XIAN, CHINA May 18, 2010 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"),]

By | 2016-02-05T04:17:03+00:00 May 18th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar